MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Latest Insider Confidence Score

2026Q1

47.1
Bearish

Company insider confidence (by quarter)

2009Q1 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Chen Lin Huey 10% Owner 2,570,947 Feb 12, 2010
Chen Lan Bo Director 2,555,787 Feb 12, 2010
Baker Bros. Advisors Lp Director 1,947,968 Aug 20, 2025
667, L.P. Director 1,947,968 Aug 20, 2025
Baker Bros. Advisors (GP) LLC Director 1,947,968 Aug 20, 2025

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Mar 4, 2026 Mar 6, 2026 Dier Mardi CFO Sell 97.5 +3,233 34.92% ✓ $854K
Mar 4, 2026 Mar 6, 2026 Sibold William John CEO Sell 92.5 +13,332 8.98% ✗ $718.3K
Mar 4, 2026 Mar 6, 2026 Kelley Shannon T General Counsel Sell 95.0 +3,657 43.12% ✗ $155.5K
Mar 4, 2026 Mar 6, 2026 Huntsman Carole Chief Commercial Officer Sell 95.0 +3,570 39.14% ✗ $181K
Mar 6, 2026 Mar 6, 2026 Taub Rebecca Director Sell 47.5 -491 -0.04% ✗ $212.1K
Mar 4, 2026 Mar 6, 2026 Soergel David Chief Medical Officer Neutral 90.0 +4,374 57.97% ✗ -
Mar 2, 2026 Mar 2, 2026 Dier Mardi CFO Sell 40.0 -1,183 -11.33% ✗ $505.4K
Feb 23, 2026 Feb 24, 2026 Levy Richard S Director Neutral 52.5 - 0.00% ✗ -
Jan 26, 2026 Jan 26, 2026 Levy Richard S Director Neutral 52.5 - 0.00% ✗ -
Jan 26, 2026 Jan 26, 2026 Huntsman Carole Chief Commercial Officer Sell 28.8 -910 -9.07% ✓ $449.3K
Jan 26, 2026 Jan 26, 2026 Sibold William John CEO Sell 40.0 -1,577 -1.05% ✗ $776.5K
Jan 26, 2026 Jan 26, 2026 Taub Rebecca Director Sell 45.0 -647 -0.06% ✗ $318.6K
Jan 20, 2026 Jan 20, 2026 Kelley Shannon T General Counsel Sell 28.8 -692 -7.54% ✓ $344.2K
Jan 20, 2026 Jan 20, 2026 Taub Rebecca Director Sell 42.5 -2,238 -0.20% ✗ $1.1M
Jan 15, 2026 Jan 20, 2026 Thakkar Rita Chief Accounting Officer Neutral 90.0 +2,398 100.00% ✗ -
Jan 20, 2026 Thakkar Rita Chief Accounting Officer Neutral 52.5 - 0.00% ✗ -
Jan 9, 2026 Jan 13, 2026 FRIEDMAN PAUL A Director Sell 55.0 -280 -0.03% ✓ $154.3K
Jan 9, 2026 Jan 13, 2026 FRIEDMAN PAUL A Director Sell 38.8 -24,520 -2.83% ✓ $12.8M
Jan 9, 2026 Jan 13, 2026 Taub Rebecca Director Sell 55.0 -240 -0.02% ✓ $132.1K
Jan 9, 2026 Jan 13, 2026 Taub Rebecca Director Sell 43.1 -18,410 -1.63% ✓ $9.6M
Dec 10, 2025 Dec 12, 2025 FRIEDMAN PAUL A Director Sell 33.8 -24,800 -2.86% ✓ $13.7M
Dec 10, 2025 Dec 12, 2025 Taub Rebecca Director Sell 33.8 -24,105 -2.12% ✓ $10.3M
Dec 3, 2025 Dec 4, 2025 Sibold William John CEO Sell 37.5 -2,400 -1.57% ✗ $1.4M
Dec 2, 2025 Dec 3, 2025 Dier Mardi CFO Sell 5.0 -4,173 -28.56% ✓ $2.4M
Nov 21, 2025 Nov 21, 2025 Huntsman Carole Chief Commercial Officer Sell 15.0 -1,958 -16.33% ✓ $1.1M
Nov 13, 2025 Nov 14, 2025 Levy Richard S Director Sell 5.0 -8,500 -28.62% ✓ $4.4M
Nov 5, 2025 Nov 7, 2025 BATE KENNETH Director Sell 16.3 -16,575 -86.32% ✗ $8M
Sep 9, 2025 Sep 9, 2025 Sibold William John CEO Sell 37.5 -7,279 -6.63% ✗ $3.2M
Aug 21, 2025 Aug 21, 2025 Sibold William John CEO Sell 27.5 -7,616 -6.49% ✓ $3M
Aug 18, 2025 Aug 20, 2025 BAKER BROS. ADVISORS LP Director Buy 72.5 +97,065 0.35% ✗ $36.9M
Aug 18, 2025 Aug 20, 2025 BAKER BROS. ADVISORS LP Director Buy 72.5 +68,618 0.24% ✗ $25M
Aug 18, 2025 Aug 18, 2025 Kelley Shannon T General Counsel Sell 22.5 -1,304 -12.45% ✓ $479.6K
Aug 15, 2025 Aug 15, 2025 BATE KENNETH Director Sell 17.5 -10,000 -79.20% ✗ $3.7M
Aug 13, 2025 Aug 13, 2025 FRIEDMAN PAUL A Director Sell 17.5 -129,172 -13.29% ✓ $47.8M
Aug 11, 2025 Aug 13, 2025 FRIEDMAN PAUL A Director Sell 37.5 -46,808 -1.48% ✓ $16.6M
Aug 11, 2025 Aug 13, 2025 Taub Rebecca Director Sell 40.0 -46,463 -0.72% ✓ $16.5M
Aug 1, 2025 Aug 5, 2025 Brennan Daniel J. Director Neutral 90.0 +967 100.00% ✗ -
Aug 5, 2025 Brennan Daniel J. Director Neutral 52.5 - 0.00% ✗ -
Jul 18, 2025 Jul 22, 2025 Taub Rebecca Director Sell 48.8 -1,000 -0.09% ✓ $350K
Jul 18, 2025 Jul 22, 2025 FRIEDMAN PAUL A Director Sell 47.5 -1,400 -0.17% ✓ $490K
Jul 16, 2025 Jul 18, 2025 FRIEDMAN PAUL A Director Sell 37.5 -28,876 -1.18% ✓ $10.2M
Jul 16, 2025 Jul 18, 2025 Taub Rebecca Director Sell 40.0 -29,101 -0.59% ✓ $10.3M
Jun 20, 2025 Jun 24, 2025 BATE KENNETH Director Neutral 90.0 +715 37.40% ✗ -
Jun 20, 2025 Jun 24, 2025 Levy Richard S Director Neutral 82.5 +715 3.49% ✗ -
Jun 20, 2025 Jun 24, 2025 FOUSE JACQUALYN A Director Neutral 90.0 +203 22.71% ✗ -
Jun 20, 2025 Jun 24, 2025 BAKER BROS. ADVISORS LP Director Neutral 55.0 +2,860 0.14% ✗ -
Jun 20, 2025 Jun 24, 2025 Daly James M Director Neutral 90.0 +715 37.40% ✗ -
Jun 20, 2025 Jun 24, 2025 FRIEDMAN PAUL A Director Neutral 55.0 +715 0.08% ✗ -
May 15, 2025 May 16, 2025 Soergel David Chief Medical Officer Neutral 90.0 +7,545 100.00% ✗ -
Apr 24, 2025 Soergel David Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Apr 10, 2025 Apr 11, 2025 Levy Richard S Director Neutral 52.5 - 0.00% ✗ -
Mar 12, 2025 Mar 14, 2025 CRAVES FRED B Director Sell 33.8 -15,470 -0.33% ✗ $5.1M
Mar 10, 2025 Mar 12, 2025 Dier Mardi CFO Sell 41.3 -258 -2.41% ✓ $83.3K
Mar 10, 2025 Mar 12, 2025 FOUSE JACQUALYN A Director Neutral 90.0 +894 100.00% ✗ -
Mar 12, 2025 FOUSE JACQUALYN A Director Neutral 52.5 - 0.00% ✗ -
Mar 5, 2025 Mar 7, 2025 Sibold William John CEO Neutral 90.0 +13,066 12.53% ✗ -
Mar 5, 2025 Mar 7, 2025 Dier Mardi CFO Neutral 90.0 +3,784 54.73% ✗ -
Mar 5, 2025 Mar 7, 2025 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 17.5 -12,052 -67.55% ✗ $4.8M
Mar 5, 2025 Mar 7, 2025 Taub Rebecca Pres., R&D, and CMO Neutral 60.0 +4,382 0.39% ✗ -
Mar 5, 2025 Mar 7, 2025 Kelley Shannon T General Counsel Neutral 90.0 +3,187 43.72% ✗ -
Mar 5, 2025 Mar 7, 2025 Huntsman Carole Chief Commercial Officer Neutral 90.0 +3,386 39.35% ✗ -
Mar 3, 2025 Mar 5, 2025 Kelley Shannon T General Counsel Sell 32.5 -415 -5.39% ✓ $139K
Mar 3, 2025 Mar 5, 2025 Dier Mardi CFO Sell 12.5 -1,961 -22.10% ✓ $637.2K
Mar 3, 2025 Mar 5, 2025 Huntsman Carole Chief Commercial Officer Sell 17.5 -1,834 -17.57% ✓ $597.8K
Feb 28, 2025 Mar 4, 2025 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 20.0 -1,227 -24.76% ✗ $418.5K
Feb 27, 2025 Feb 28, 2025 Sibold William John CEO Neutral 52.5 - 0.00% ✗ -
Feb 27, 2025 Feb 28, 2025 Daly James M Director Sell 16.3 -15,470 -89.00% ✗ $5.4M
Feb 27, 2025 Feb 28, 2025 BATE KENNETH Director Sell 16.3 -20,000 -91.27% ✗ $7.1M
Jan 24, 2025 Jan 27, 2025 Huntsman Carole Chief Commercial Officer Sell 42.5 -347 -3.22% ✗ $116.3K
Jan 24, 2025 Jan 27, 2025 Sibold William John CEO Sell 40.0 -1,584 -2.83% ✗ $531K
Jan 24, 2025 Jan 27, 2025 Taub Rebecca Pres., R&D, and CMO Sell 47.5 -648 -0.06% ✗ $217.2K
Jan 24, 2025 Jan 27, 2025 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 46.3 -103 -2.04% ✗ $34.5K
Jan 17, 2025 Jan 17, 2025 Kelley Shannon T General Counsel Sell 42.5 -277 -3.47% ✗ $75.7K
Jan 17, 2025 Jan 17, 2025 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 42.5 -442 -8.04% ✗ $120.8K
Jan 17, 2025 Jan 17, 2025 Taub Rebecca Pres., R&D, and CMO Sell 45.0 -1,689 -0.15% ✗ $461.8K
Dec 3, 2024 Dec 5, 2024 CRAVES FRED B Director Sell 27.5 -3,600 -0.93% ✗ $1.1M
Nov 25, 2024 Nov 27, 2024 CRAVES FRED B Director Sell 27.5 -3,400 -0.87% ✗ $1.2M
Nov 21, 2024 Nov 22, 2024 Huntsman Carole Chief Commercial Officer Sell 42.5 -688 -6.00% ✗ $218K
Nov 7, 2024 Nov 8, 2024 Levy Richard S Director Sell 5.0 -5,000 -31.23% ✓ $1.8M
Nov 1, 2024 Nov 5, 2024 Levy Richard S Director Sell 5.0 -5,000 -31.23% ✓ $1.5M
Sep 13, 2024 Sep 17, 2024 CRAVES FRED B Director Neutral 27.5 -15,000 -3.70% ✗ -
Sep 9, 2024 Sep 11, 2024 Sibold William John CEO Sell 37.5 -6,363 -10.22% ✗ $1.6M
Aug 15, 2024 Aug 19, 2024 Kelley Shannon T General Counsel Neutral 90.0 +5,215 188.47% ✗ -
Aug 15, 2024 Kelley Shannon T General Counsel Neutral 52.5 - 0.00% ✗ -
Jun 25, 2024 Jun 27, 2024 CRAVES FRED B Director Neutral 55.0 +714 0.18% ✗ -
Jun 25, 2024 Jun 27, 2024 BATE KENNETH Director Neutral 90.0 +714 59.60% ✗ -
Jun 25, 2024 Jun 27, 2024 Daly James M Director Neutral 90.0 +714 59.60% ✗ -
Jun 25, 2024 Jun 27, 2024 Levy Richard S Director Neutral 85.0 +714 6.93% ✗ -
Jun 25, 2024 Jun 27, 2024 FRIEDMAN PAUL A Director Neutral 55.0 +714 0.08% ✗ -
Jun 25, 2024 Jun 27, 2024 BAKER BROS. ADVISORS LP Director Neutral 55.0 +2,856 0.14% ✗ -
Jun 14, 2024 Jun 18, 2024 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 20.0 -1,900 -25.68% ✗ $532K
Jun 12, 2024 Jun 14, 2024 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 20.0 -2,000 -26.67% ✗ $570K
Jun 11, 2024 Jun 13, 2024 CRAVES FRED B Director Neutral 27.5 -84,852 -18.04% ✗ -
May 21, 2024 May 23, 2024 Waltermire Robert E. Senior VP, Chief Pharma Dev. Sell 22.5 -1,036 -15.85% ✗ $239.7K
May 14, 2024 May 16, 2024 CRAVES FRED B Director Sell 32.5 -22,489 -4.39% ✓ $4.8M
Apr 8, 2024 Apr 10, 2024 Taub Rebecca Pres., R&D, and CMO Sell 47.5 -2,676 -0.24% ✓ $658.3K
Apr 8, 2024 Apr 10, 2024 FRIEDMAN PAUL A Director Sell 31.3 -26,270 -3.03% ✓ $6.5M
Apr 3, 2024 Apr 5, 2024 Taub Rebecca Pres., R&D, and CMO Sell 40.0 -73,888 -0.77% ✓ $18M
Apr 3, 2024 Apr 5, 2024 FRIEDMAN PAUL A Director Sell 37.5 -73,730 -1.59% ✓ $18M
Apr 1, 2024 Apr 3, 2024 Levy Richard S Director Sell 5.0 -11,000 -51.65% ✓ $2.8M